应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BMY 施贵宝
交易中 08-14 11:59:21 EDT
63.71
-0.94
-1.46%
最高
64.25
最低
63.35
成交量
241.66万
今开
64.07
昨收
64.65
日振幅
1.39%
总市值
1,297亿
流通市值
1,294亿
总股本
20.36亿
成交额
1.54亿
换手率
0.12%
流通股本
20.32亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤
格隆汇 · 10:28
施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤
美国FDA加速批准百时美施贵宝首款Celmod疗法Zenbexus™联合用药方案，用于多发性骨髓瘤首次复发患者
美股速递 · 05:13
美国FDA加速批准百时美施贵宝首款Celmod疗法Zenbexus™联合用药方案，用于多发性骨髓瘤首次复发患者
FDA加速批准Iberdomide联合Daratumumab与透明质酸酶及地塞米松用于多发性骨髓瘤治疗
美股速递 · 04:13
FDA加速批准Iberdomide联合Daratumumab与透明质酸酶及地塞米松用于多发性骨髓瘤治疗
Cytokinetics对百时美施贵宝提起专利侵权诉讼。
智通财经 · 08-13 21:31
Cytokinetics对百时美施贵宝提起专利侵权诉讼。
Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税
美股速递 · 08-13 20:03
Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税
Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作
美股速递 · 08-13 20:02
Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作
Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动
美股速递 · 08-13 20:01
Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动
黄仁勋5000亿融资“撕裂市场”：资管巨头狂欢，科技股两日连跌
华尔街见闻 · 08-12 08:45
黄仁勋5000亿融资“撕裂市场”：资管巨头狂欢，科技股两日连跌
施贵宝将斥资23亿美元在休斯顿新建生产设施
格隆汇 · 08-11
施贵宝将斥资23亿美元在休斯顿新建生产设施
百时美施贵宝斥资23亿美元在休斯敦建设制药基地，扩大美国制造布局
老虎资讯综合 · 08-10
百时美施贵宝斥资23亿美元在休斯敦建设制药基地，扩大美国制造布局
施贵宝大手笔投入23亿美元，得州休斯顿新建美国制造园区
美股速递 · 08-10
施贵宝大手笔投入23亿美元，得州休斯顿新建美国制造园区
施贵宝预计2027-2030年间将创造2000个建筑与间接就业岗位
美股速递 · 08-10
施贵宝预计2027-2030年间将创造2000个建筑与间接就业岗位
Prothena有望获5500万美元临床里程碑付款——取决于施贵宝是否推动PRX019项目，预计2026年底揭晓
美股速递 · 08-07
Prothena有望获5500万美元临床里程碑付款——取决于施贵宝是否推动PRX019项目，预计2026年底揭晓
异动解读｜施贵宝盘中下跌3.19%，知情人士否认与阿斯利康合并传闻
行情直击 · 08-05
异动解读｜施贵宝盘中下跌3.19%，知情人士否认与阿斯利康合并传闻
美股异动｜阿斯利康反弹涨超4%，消息人士否认与施贵宝合并传闻
格隆汇 · 08-05
美股异动｜阿斯利康反弹涨超4%，消息人士否认与施贵宝合并传闻
阿斯利康股价大涨，消息称目前未与百时美施贵宝进行并购谈判后，该股日内涨幅现已达到3.5%。
智通财经 · 08-05
阿斯利康股价大涨，消息称目前未与百时美施贵宝进行并购谈判后，该股日内涨幅现已达到3.5%。
市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论
老虎资讯综合 · 08-05
市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论
百时美施贵宝股价盘前交易迅速下跌2.3%。
智通财经 · 08-05
百时美施贵宝股价盘前交易迅速下跌2.3%。
异动解读｜施贵宝盘前下跌3.14%，RBC称与阿斯利康合并可能性极低
行情直击 · 08-05
异动解读｜施贵宝盘前下跌3.14%，RBC称与阿斯利康合并可能性极低
独家消息：知情高层透露，阿斯利康与施贵宝之间“从未有过交易可谈”
美股速递 · 08-05
独家消息：知情高层透露，阿斯利康与施贵宝之间“从未有过交易可谈”
加载更多
公司概况
公司名称：
施贵宝
所属市场：
NYSE
上市日期：
--
主营业务：
百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。
发行价格：
--
{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":63.705,"timestamp":1786723161608,"preClose":64.65,"halted":0,"volume":2416562,"delay":0,"changeRate":-0.014617169373549998,"floatShares":2031646263,"shares":2035753027,"eps":4.542906,"marketStatus":"交易中","change":-0.945,"latestTime":"08-14 11:59:21 EDT","open":64.07,"high":64.25,"low":63.35,"amount":153895923.59246,"amplitude":0.013921,"askPrice":63.71,"askSize":174,"bidPrice":63.7,"bidSize":414,"shortable":3,"etf":0,"ttmEps":4.542906,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786737600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":64.65,"dividendRate":0.039389,"preHourTrading":{"tag":"盘前","latestPrice":64.45,"preClose":64.65,"latestTime":"09:29 EDT","volume":3042,"amount":196894.54512,"timestamp":1786714194385,"change":-0.2,"changeRate":-0.003094,"amplitude":0.008507},"postHourTrading":{"tag":"盘后","latestPrice":64.77,"preClose":64.65,"latestTime":"19:54 EDT","volume":621701,"amount":40193573.9955,"timestamp":1786665277032,"change":0.12,"changeRate":0.001856,"amplitude":0.003094},"volumeRatio":0.708054,"impliedVol":0.2755,"impliedVolPercentile":0.2032},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"2659219498","title":"施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2659219498","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659219498?lang=zh_cn&edition=full","pubTime":"2026-08-14 10:28","pubTimestamp":1786674495,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4559","LU0225771236.USD","IHE","LU2360032135.SGD","FTXH","LU0868494617.USD","LU1093756325.SGD","LU0237698245.USD","LU0306806265.USD","IE0009355771.USD","LABU","IE00BSNM7G36.USD","LU2125154935.USD","LU1291159041.SGD","LU2133065610.SGD","LU2125154778.USD","LU0061475181.USD","IE00BJT1NW94.SGD","LU0225284248.USD","BK4581","LU1074936037.SGD","LU1032466523.USD","IE0002141913.USD","LU1093756168.USD","LU0267386448.USD","BK4534","BK4588","LU1261432733.SGD","LU0882574055.USD","LU1868836591.USD","LU1868837136.USD","LU0096364046.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU0321505868.SGD","IE00B2B36J28.USD","LU1868836914.USD","LU0306807586.USD","LU2242652126.USD","LU1670710588.SGD","LU1868836757.USD","LU1983299246.USD","LU1323610961.USD","BMY","LU1718418525.SGD","LU1670710661.SGD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU1989771016.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179303038","title":"美国FDA加速批准百时美施贵宝首款Celmod疗法Zenbexus™联合用药方案，用于多发性骨髓瘤首次复发患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1179303038","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179303038?lang=zh_cn&edition=full","pubTime":"2026-08-14 05:13","pubTimestamp":1786655593,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予加速批准，同意百时美施贵宝（Bristol Myers Squibb）旗下首款Celmod疗法——Zenbexus™，与达雷妥尤单抗、透明质酸酶-Fihj以及地塞米松联合组成Zdd方案，用于治疗多发性骨髓瘤患者。这一批准适用于从首次复发阶段起，即可启用该疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","IE00BJT1NW94.SGD","LU1989771016.USD","IE00BFXG1179.USD","BMY","BK4007","IE0009355771.USD","LU0306806265.USD","IE0002141913.USD","LU0267386448.USD","LU0432979614.USD","LU1868836757.USD","LU1670711040.USD","BK4559","LU0456855351.SGD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU1670710661.SGD","LU1883839398.USD","BK4585","LU1032466523.USD","LU1868836914.USD","LU2242652126.USD","LU0237698245.USD","LU0225284248.USD","LU1670711123.USD","LU2360032135.SGD","LU1093756168.USD","LU1430594728.SGD","LU0114720955.EUR","LU1868837300.USD","LU1868836591.USD","IHE","LU0985481810.HKD","LU1261432733.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4534","BK4532","LU1571399168.USD","LU0096364046.USD","LU1074936037.SGD","LU0321505439.SGD","LU1670710588.SGD","LU1093756325.SGD","LU1291159041.SGD","LU2242646821.SGD","BK4588","LU1323610961.USD","LU0225771236.USD","LU0882574055.USD","LU1868837136.USD","LU2125154935.USD","LU1718418525.SGD","LU0306807586.USD","LU2133065610.SGD","LU0061475181.USD","LU1983299246.USD","LU1585245621.USD","LU0868494617.USD","FTXH","LU2596442595.SGD","LU2125154778.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115777296","title":"FDA加速批准Iberdomide联合Daratumumab与透明质酸酶及地塞米松用于多发性骨髓瘤治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1115777296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115777296?lang=zh_cn&edition=full","pubTime":"2026-08-14 04:13","pubTimestamp":1786652015,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予Iberdomide联合Daratumumab、透明质酸酶-Fihj以及地塞米松的加速批准，用于治疗多发性骨髓瘤。这一组合疗法为患者带来了新的治疗选择。其中，Iberdomide是施贵宝（Bristol-Myers Squibb）研发的一款创新药物。此次批准基于临床试验中展现出的显著疗效，标志着在对抗这一血液系统恶性肿瘤方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306806265.USD","LU1670711123.USD","LU2360032135.SGD","LU1430594728.SGD","BK4581","BK4585","LU1585245621.USD","LU1670711040.USD","LU1868837136.USD","BK4559","LU0321505439.SGD","LU0237698245.USD","LU2133065610.SGD","LU1093756168.USD","BMY","FTXH","LU1718418525.SGD","LU0985481810.HKD","LU2596442595.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU2125154935.USD","BK4532","BK4588","LU0432979614.USD","LU0868494617.USD","IE0009355771.USD","LU1323610961.USD","LU2242652126.USD","LU1291159041.SGD","IE00BFXG1179.USD","LU0225771236.USD","LU1032466523.USD","BK4534","LU2125154778.USD","LU0456855351.SGD","IHE","LU1670710588.SGD","LU0882574055.USD","LU1670710661.SGD","LU1571399168.USD","LU1868836914.USD","IE00BSNM7G36.USD","LU1074936037.SGD","LU1868836591.USD","LU1989771016.USD","LU1093756325.SGD","LU0096364046.USD","BK4007","LU1261432733.SGD","LU0114720955.EUR","LU1983299246.USD","LU1868836757.USD","IE0002141913.USD","LU0225284248.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1883839398.USD","LU0321505868.SGD","LU0061475181.USD","LU0267386448.USD","IE00BJT1NW94.SGD","LU0306807586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659301150","title":"Cytokinetics对百时美施贵宝提起专利侵权诉讼。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659301150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659301150?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:31","pubTimestamp":1786627862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4534","LU2125154778.USD","BK4588","LU2360032135.SGD","IE00BJT1NW94.SGD","IHE","LU0267386448.USD","LU1670710661.SGD","CYTK","LU2242652126.USD","LU1868837136.USD","LU0061475181.USD","IE00BJJMRZ35.SGD","LU0882574055.USD","LU2125154935.USD","LU0868494617.USD","LU1670711040.USD","BMY","LU1989771016.USD","IE0009355771.USD","LU1585245621.USD","LU1430594728.SGD","LU1093756168.USD","IE00BFXG1179.USD","BK4532","BK4139","IE0002141913.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","BK4505","LU0456855351.SGD","LU0306806265.USD","LU1718418525.SGD","LU2242646821.SGD","BK4559","LU0225771236.USD","LU0306807586.USD","LU2596442595.SGD","BK4585","IE00BSNM7G36.USD","LU1868836591.USD","FTXH","LU1868836914.USD","IE00B2B36J28.USD","LU0096364046.USD","LU0225284248.USD","LU1074936037.SGD","LU0432979614.USD","LU1291159041.SGD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120034487","title":"Atrium Therapeutics 获资格：研发里程碑可高达13.5亿美元，商业里程碑达8.25亿美元，另享阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1120034487","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120034487?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:03","pubTimestamp":1786622625,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics 公司已具备获得里程碑付款的资格。具体来看，其研发里程碑款项总额最高可达13.5亿美元。与此同时，商业里程碑的潜在金额也相当可观，达到了8.25亿美元。此外，该公司还将有权收取阶梯式版税。这一系列激励措施，为这家生物技术公司注入了强劲的发展动力，也凸显了其候选药物的巨大商业潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711040.USD","LU1670711123.USD","BMY","BK4139","LU0432979614.USD","BK4585","LU1868836591.USD","LU2242646821.SGD","RNA","LU0306807586.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU1868837300.USD","LU1291159041.SGD","LU0096364046.USD","IE00BFTCPJ56.SGD","LU0267386448.USD","BK4588","BK4007","IE0002141913.USD","LU0868494617.USD","LU1983299246.USD","BK4581","LU1868836757.USD","IE00BSNM7G36.USD","LU1093756325.SGD","LU1989771016.USD","LU1670710661.SGD","LU1718418525.SGD","IE0009355771.USD","LU0321505868.SGD","LU2360032135.SGD","BK4534","LU1032466523.USD","FTXH","BK4505","LU0321505439.SGD","LU0456855351.SGD","LU1670710588.SGD","LU2596442595.SGD","BK4559","LU1323610961.USD","BK4532","LU2125154935.USD","LU2242652126.USD","IHE","LU0061475181.USD","IE0009354923.USD","LU1571399168.USD","LU1585245621.USD","IE00B2B36J28.USD","LU1883839398.USD","LU1093756168.USD","IE00BFXG1179.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU1868837136.USD","LU2125154778.USD","LU0985481810.HKD","LU1261432733.SGD","LU2133065610.SGD","LU0225284248.USD","LU1868836914.USD","LU0306806265.USD","LU1430594728.SGD","LU1074936037.SGD","LU0225771236.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176688754","title":"Atrium Therapeutics 获施贵宝1500万美元里程碑付款，源于全球心血管合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1176688754","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176688754?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:02","pubTimestamp":1786622555,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics 宣布，已从百时美施贵宝（Bristol Myers Squibb）获得一笔1500万美元的里程碑付款，这笔款项是基于双方此前达成的全球心血管疾病合作项目所产生的。此次付款标志着双方合作在研发或临床推进方面取得了关键性进展，进一步巩固了这两家公司在心血管治疗领域的战略联盟。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0882574055.USD","BK4505","BK4532","BK4588","LU0456855351.SGD","LU2242652126.USD","LU0321505868.SGD","IE0002141913.USD","LU1323610961.USD","RNA","BMY","IE00BSNM7G36.USD","LU1093756168.USD","LU1291159041.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0237698245.USD","LU0306807586.USD","LU1032466523.USD","LU0114720955.EUR","LU1670711123.USD","LU0225284248.USD","IHE","FTXH","LU0096364046.USD","LU1430594728.SGD","LU1585245621.USD","LU1670710588.SGD","LU1868836914.USD","LU1868836591.USD","LU2125154935.USD","BK4581","LU1868837136.USD","LU1989771016.USD","LU1983299246.USD","LU0225771236.USD","LU0985481810.HKD","BK4534","IE00BFXG1179.USD","LU2242646821.SGD","LU0868494617.USD","LU1718418525.SGD","LU1868837300.USD","BK4585","LU0061475181.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU1670711040.USD","BK4139","BK4559","LU0321505439.SGD","LU1868836757.USD","LU1883839398.USD","LU0432979614.USD","BK4007","LU1670710661.SGD","LU1261432733.SGD","LU0267386448.USD","LU2125154778.USD","LU0306806265.USD","LU2596442595.SGD","LU1074936037.SGD","LU2360032135.SGD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182050958","title":"Atrium Therapeutics（RNA）获施贵宝全额资助，未来开发与商业化活动全面启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1182050958","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182050958?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:01","pubTimestamp":1786622485,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，制药巨头Bristol Myers Squibb将为其后续所有开发及商业化活动提供全额资金支持。这一战略合作标志着Atrium Therapeutics在创新疗法领域迈出关键一步，同时彰显了施贵宝对RNA平台技术潜力的强烈信心。根据协议，施贵宝将承担从临床研究到市场推广的全链条成本，从而大幅降低Atrium Therapeutics的财务风险，并加速其候选药物的上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1883839398.USD","LU1074936037.SGD","BK4559","LU2360032135.SGD","LU0114720955.EUR","LU0225771236.USD","LU0868494617.USD","LU0096364046.USD","RNA","LU1093756168.USD","LU1323610961.USD","LU1868836591.USD","LU1261432733.SGD","BK4585","LU1670710661.SGD","LU0225284248.USD","LU0985481810.HKD","LU1032466523.USD","LU0321505868.SGD","LU1430594728.SGD","LU1983299246.USD","LU0882574055.USD","LU2242652126.USD","BK4007","BK4139","BK4532","BK4581","LU1670711123.USD","BMY","IE00BSNM7G36.USD","LU2125154778.USD","LU1670711040.USD","LU2125154935.USD","LU0306806265.USD","IHE","LU0321505439.SGD","IE0009354923.USD","LU1989771016.USD","LU2133065610.SGD","IE00B2B36J28.USD","BK4588","LU2596442595.SGD","LU1718418525.SGD","LU1291159041.SGD","LU1093756325.SGD","LU1670710588.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0267386448.USD","LU0432979614.USD","LU1868836914.USD","LU0061475181.USD","LU1868836757.USD","BK4505","LU1585245621.USD","LU0306807586.USD","LU0237698245.USD","LU0456855351.SGD","IE00BFTCPJ56.SGD","FTXH","IE0009355771.USD","LU1868837300.USD","LU1571399168.USD","IE00BFXG1179.USD","LU2242646821.SGD","LU1868837136.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194289","title":"黄仁勋5000亿融资“撕裂市场”：资管巨头狂欢，科技股两日连跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194289","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658194289?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:45","pubTimestamp":1786495546,"startTime":"0","endTime":"0","summary":"市场将这一融资安排解读为对私募信贷和另类投资的直接利好——庞大的资金管道意味着管理费收入的长期增长前景，KKR、阿波罗等另类资管巨头股价大涨3%至7%，但大型科技股连续承压。这一分化折射出深层隐忧：英伟达亲自为客户找融资，究竟是需求强劲还是需求需靠融资\"创造\"？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3779236","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDW","LU0772969993.USD","LU2125909759.SGD","IE00BK4W5M84.HKD","LU2394011477.USD","LU2896262040.SGD","LU2505996509.AUD","SG9999018857.SGD","LU0174119429.USD","NVD","LU0310799852.SGD","LU1674673691.USD","LU0648001328.SGD","LU0130102774.USD","LU2750360641.GBP","HK0000320223.HKD","IE00BFSS8Q28.SGD","LU1093756325.SGD","LU1852331112.SGD","SG9999014880.SGD","LU2326559502.SGD","CHPX","LU1935042991.SGD","HK0000306685.HKD","LU0256863811.USD","LU0211328371.USD","LU0080751232.USD","LU2168564065.EUR","BK4503","NVDS","BK4612","LU2322448791.USD","BK4559","GB00BDT5M118.USD","LU0289961442.SGD","LU0215105999.USD","LU2452424414.USD","BK4581","3NVD.UK","IE0004091025.USD","LU0314104364.USD","LU0154236417.USD","LU2286300806.USD","IE000W1ABFV2.USD","LU0528227936.USD","LU1935042215.USD","BK4127","LU1712237335.SGD","LU2168564495.EUR","IE00BMPRXR70.SGD","TEK","IE00B3QW5Z07.USD","LU1400636491.USD","IE0009G5SDU7.USD","HK0000304805.HKD","LU1923623000.USD","LU1992135472.HKD","LU0203202063.USD","LU0731783048.USD","LU0820562030.AUD","LU1242518857.USD","LU0107464264.USD","LU0234572021.USD","LU1429558221.USD","LU1599440770.SGD","IE0004445015.USD","IE0002141913.USD","LU1861215975.USD","LU2065169927.USD","IE00B3M56506.USD","LU0738911758.USD","IE00B19Z8W00.USD","IE00BWXC8680.SGD","LU2264538146.SGD","LU1868837300.USD","LU0965508806.USD","LU2746668461.USD","USD","IE000ITXATA3.USD","SG9999001424.SGD","SG9999014898.SGD","LU0787776722.HKD","IE00BKVL7J92.USD","IE00BJJMRX11.SGD","GPZ","TRFK","LU2471134523.USD","IE00B19Z3581.USD","IE00BQXX3F31.USD","LU0310800379.SGD","LU1119994496.HKD","LU1983299246.USD","LU0077335932.USD","BK4529","SOXX","LU2360106780.USD","LU2491050071.SGD","LU0234570918.USD","LU0823434740.USD","LU1244550494.USD","LU1280957306.USD","NVDO","ESUM","LU2491049909.HKD","LU0210536198.USD","IE00B4YYXB79.USD","BK4548","LU1366333091.USD","LU0820561909.HKD","LU1481011911.USD","LU1629891620.HKD","LU0545039389.USD","LU0494093205.USD","LU1868837136.USD","LU0466842654.USD","LU0048584097.USD","LU0289739343.SGD","IE00BVYPNV92.GBP","LU1400636657.SGD","LU1934455194.USD","IE0003U64NQ7.SGD","NVDD","LU1201861249.SGD","WISE","LU2357305700.SGD","LU2756315318.SGD","LU2381873111.SGD","SGXZ99366536.SGD","CNEQ","SGXZ81514606.USD","AIPI","LU2954938101.SGD","LU0965509101.SGD","LU1074936037.SGD","LU2430703095.HKD","LU0251132253.USD","LU0198837287.USD","LU0985320562.USD","IE00BGHQF631.EUR","LU2433249047.HKD","LU2106854487.HKD","LU0276348264.USD","IE00BZ199S13.USD","LU0225283273.USD","PRVT","LU1069344957.HKD","LU2430703178.SGD","LU1066051225.USD","LU1670710661.SGD","LU2461242641.AUD","SPTE","LU1720051108.HKD","LU0719512351.SGD","NVDG","LU1868836591.USD","BK4007","IE00BQXX3D17.EUR","IE00BDCRKT87.USD","IE00BJTD4N35.SGD","LU2471134879.HKD","TTEQ","HK0000819398.USD","LU1244550221.USD","LU0096362180.USD","LU2543165471.USD","LU2213496289.HKD","LU2125154778.USD","LU0251131958.USD","IE00BN29S564.USD","IE00BVYPNW00.USD","LU0689626769.HKD","FAI","LU1642822529.SGD","SG9999017495.SGD","LU1732800096.USD","LU0395794307.EUR","LU1815333072.USD","LU1868836757.USD","AIFD","LU2092937148.SGD","NULC","LU2125909247.SGD","LU1066053197.SGD","LU0057025933.USD","IE00BMPRXQ63.HKD","LU0208291251.USD","LU0133085943.USD","LU1988902786.USD","LU0006061336.USD","LU2249611893.SGD","SMHX","LU2637965513.SGD","LU1069347547.HKD","LU2458330243.SGD","LU0267386448.USD","SG9999015341.SGD","LU2237443465.HKD","LU2462157665.USD","BK4567","TYLG","LU0724617625.USD","LU2471134796.USD","NVII","LU2242650005.HKD","LU1548497426.USD","LU0106831901.USD","LU1032466523.USD","LU0266013472.USD","LU2247934214.USD","LU1116320737.USD","ROM","LU0061475181.USD","07788","IE00B19Z3B42.SGD","EFIV","LU1670711123.USD","LU1496350502.SGD","LU0289960550.SGD","LU0274383776.USD","LU2092627202.USD","LU2506951792.HKD","BK4504","LU0642271901.SGD","LU2237957902.USD","LU0965509010.AUD","LU2242652126.USD","IE00B42XCP33.USD","LU0345769631.USD","BK4527","BK4614","KKR","LU1935043023.USD","LU2271345857.HKD","IE00BGHQF748.EUR","LU0082616367.USD","LU1951200564.SGD","SG9999014575.USD","LU0943347566.SGD","LU1894683264.USD","LU2065171311.SGD","07388","LU0980610538.SGD","LU1202635105.USD","LU2047632596.USD","LU2250418816.HKD","IXN","LU2999663052.SGD","SG9999018865.SGD","LU1880398554.USD","IE00BSNM7G36.USD","HK0000304797.USD","BK4608","LU0823421416.USD","FTXH","LU0069063385.USD","LU1670710588.SGD","LU2244417387.USD","LU1093756168.USD","LU0306807586.USD","BK4551","LU2322448957.HKD","LU2168563687.JPY","LU1585245621.USD","SG9999015358.SGD","IE000YTNTUN2.SGD","LU1670627923.USD","LU1989771016.USD","LU1989764748.USD","LU0265550946.USD","LU1366192091.USD","LU0238689110.USD","IE00B5TLWC47.USD","LU2133065610.SGD","LU0128525929.USD","LU2191332357.HKD","LU2272731600.USD","LU2458330169.SGD","LU1670756490.USD","LU2279689827.SGD","LU2756315664.SGD","LU0316494557.USD","LU1983260115.SGD","LU0265550359.USD","LU1633808545.USD","USXF","LU0321505439.SGD","FDTX","LU1066051811.HKD","LU0109391861.USD","LU2860962120.EUR","LU0823414478.USD","IE00BJJMRY28.SGD","LU1496350171.SGD","IE0009355771.USD","DIPS","LU0661504455.SGD","IE0034235295.USD","LU1267930490.SGD","LU1718418525.SGD","GS","IE00BKPKM429.USD","LU0187121727.USD","IE0034235303.USD","LU2237957811.SGD","LU2083900584.USD","LU0094547139.USD","LU0106261372.USD","BK4552","IE0004445239.USD","HK0000320264.USD","LU1035775433.USD","JGRO","LU1084165304.USD","IETC","LU3102509885.SGD","LU0320765489.SGD","LU0417517546.SGD","LU0237698245.USD","LU2023250504.SGD","2NVD.UK","LU0889565833.HKD","LU2471134952.CNY","LU2272731865.HKD","LU1861220033.SGD","LU0061474960.USD","SG9999014542.SGD","LU0979878070.USD","LU2430703251.USD","LU1934455277.USD","LU2108987350.USD","LU0965509283.SGD","LU1400636574.HKD","LU0056508442.USD","IE000Q6AESB8.SGD","LU2746668974.SGD","IE00BLSP4239.USD","LU2100268510.USD","NVDS.UK","LU2089283258.USD","LU0557290698.USD","BK4585","LU1037948897.HKD","BX","LU0882574055.USD","LU1674673428.USD","APO","LU0795875086.SGD","LU0127658192.USD","LU1861127337.USD","LU1267930730.SGD","LU1721428933.USD","LU2462591277.SGD","LU0708994859.HKD","SG9999015952.SGD","LU2602419157.SGD","LU0029864427.USD","LU1668664300.SGD","LU2361044949.HKD","LU0444971666.USD","LU0306806265.USD","LU0353189763.USD","IE000KEQY171.SGD","LU1323610961.USD","LU2750360997.AUD","IE00BHPRN162.USD","BK4579","LU0957791311.USD","LU0203201768.USD","LU2403377893.USD","LU1821325948.USD","LU2491050154.USD","IE0034235188.USD","LU0048573561.USD","LU2462591350.SGD","LU1814569148.SGD","IE0009356076.USD","IE0001KFT4U8.USD","BK4532","LU1815336760.USD","LU1880398471.USD","LU2417539215.USD","BK4543","IE00BKDWB100.SGD","NVDY","LU1037948541.HKD","LU1992135399.USD","LU0672654240.SGD","LU2125909916.SGD","BK4587","LU1261432733.SGD","LU1481011671.HKD","LU0323240290.USD","LU1670711040.USD","LU2065170008.USD","NVDU","LU0553294199.USD","LU2361045086.USD","IE00B19Z9505.USD","LU1623119135.USD","LU2347655156.SGD","SG9999004303.SGD","LU0390134368.USD","LU0476273544.USD","LU0109392836.USD","AGOX","LU0097036916.USD","LU0072462426.USD","LU1551013342.USD","LU2552382132.HKD","IE00B775H168.HKD","LU0345770993.USD","LU0158827948.USD","LU0342679015.USD","BK4605","LU2077746001.SGD","LU1145028129.USD","LU1509826696.USD","LU0786609619.USD","LU1917777945.USD","LU0170899867.USD","BK4516","BK4534","IE00BLSP4452.SGD","CHAT","LU1989764664.SGD","IE00BD6J9T35.USD","IE00B2B36J28.USD","LU0323239441.USD","LU1035773651.USD","LU2237438978.USD","LU0079474960.USD","SOXY","LU1691799644.USD","SG9999015978.USD","LU2242649171.HKD","LU2111349929.HKD","IE00B3SWFQ91.USD","LU0061474705.USD","LU2028103732.USD","LU2360107168.USD","LU0138981039.USD","SG9999014567.USD","LU2023251221.USD","ILDR","LU1791710582.SGD","LU0210533765.USD","IE00BFTCPJ56.SGD","LU2456880835.USD","LU0820561818.USD","LU1291159041.SGD","LU2089985449.USD","LU0345769128.USD","HK0000914660.USD","IE00BQXX3C00.GBP","LU1923622291.USD","HK0000306701.USD","BK4554","LU0175139822.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","SG9999002224.SGD","SGXZ23171101.USD","IE00B3PB1722.GBP","TTXU","IE00B4JS1V06.HKD","LU2065171402.SGD","SOXQ","LU0256863902.USD","NVDB","LU2237443622.USD","LU1914381329.SGD","LU1979441026.SGD","LU2087625088.SGD","FTEC","ESLG","LU2265009873.SGD","LU2294711713.HKD","IE00BJTD4V19.USD","LU0210528500.USD","ARTY","IE00BYXW3230.USD","LU0225284248.USD","LU1778281490.HKD","LU0211327993.USD","IE00BJLML261.HKD","LU2242646821.SGD","IE00B5949003.HKD","LU1791807156.HKD","LU0114720955.EUR","LU2360032135.SGD","LU0353189680.USD","BK4141","LU2097344431.USD","VT","BMY","LU0640476718.USD","LU1699723380.USD","IE00BJJMRZ35.SGD","IE00BDRTCR15.USD","BK4184","LU2237443978.SGD","LU0868494617.USD","LU0912757837.SGD","LU2148611432.USD","ABFL","HK0000532082.HKD","BK4588","BK4533","LU1645745479.HKD","LU0323591593.USD","LU0081259029.USD","LU0006306889.USD","BK4592","LU0345768153.USD","LU2413666699.HKD","LU0070217475.USD","LU1670628061.USD","LU0321505868.SGD","LU0742534661.SGD","LU0795875169.SGD","SG9999002232.USD","GSX","SNPE","LU2361044865.SGD","BK4135","SG9999014914.USD","NVDX","ANV","LU0354030511.USD","LU1974910355.USD","FDFF","IE00B775SV38.USD","LU1066051498.USD","NVD2.UK","SG9999015986.USD","SG9999015945.SGD","LU1935043536.SGD","LU0472753341.HKD","LU1116320901.HKD","LU2505996681.GBP","LU1989772923.USD","LU1791710400.SGD","LU0708995401.HKD","GAMR","LU0731783394.SGD","IE00BK4W5L77.USD","LU2592432038.USD","IE00BFXG1179.USD","LU1232071149.USD","LU1732799900.SGD","LU0683600562.USD","THMR","LU2125154935.USD","LU0308772762.SGD","LU2596442595.SGD","LU0957808578.USD","LU2552382058.USD","BK4535","LU2272731782.SGD","PSP","LU2290526834.HKD","IE0004086264.USD","SGXZ31699556.SGD","LU0949170772.SGD","LU1551013425.SGD","NVDA","METV","IE00B19Z8X17.USD","LU1153585028.USD","LU2125909593.SGD","LU0251142724.SGD","LU0942090050.USD","IE00BFSS7M15.SGD","SNVD.UK","SHOC","IE00BBT3K403.USD","LU0225771236.USD","LU0157215616.USD","LU2097344357.USD","LU1804176565.USD","IE00B64PRP62.GBP","LU0823434583.USD","SG9999014906.USD","LU2054465674.USD","LU0124676726.USD","LU1244550577.SGD","LU2473716301.USD","LU0347712357.USD","LU1267930573.SGD","LU2237443549.SGD","LU0823414551.USD","LU0354030438.USD","LU1883839398.USD","LU1923622614.USD","IE00B1XK9C88.USD","NVDQ","LU1935042488.USD","LU2023250330.USD","LU1064131342.USD","LU0964807845.USD","LU0096364046.USD","LU1316542783.SGD","LU1720051017.SGD","CMAG","IE00B7KXQ091.USD","BK4550","LU2089284900.SGD","IE00BMPRXN33.USD","LU1430594728.SGD","LU1839511570.USD","SGXZ51526630.SGD","LU0456855351.SGD","IE00B3S45H60.SGD","LU1571399168.USD","LU0689472784.USD","LU0823421333.USD","LU1127390331.HKD","LU1868836914.USD","LU2552382215.SGD","BK4549","BLK","NVDL","LU2087621335.USD","LU2168564149.EUR","LU0511384066.AUD","LU0320765059.SGD","NVD3.UK","LU1435385759.SGD","IE0005OL40V9.USD","LU0345768740.USD","LU2413666426.HKD","LU0432979614.USD","LFGY","NVYY","IE0002270589.USD","LU0868494708.USD","LU1803068979.SGD","LU1894683348.USD","SGXZ80539844.SGD","LU2463028550.USD","LU0143551892.USD","LU0348723411.USD","LU2420271590.USD","LU1989772840.SGD","LU0861579265.USD","LU0742537680.HKD","LU0345770308.USD","LU0053666078.USD","SG9999000418.SGD","LBO","LU1951198990.SGD","LU0726765562.USD","LU2357125470.USD","IHE","LU1242518931.SGD","LU0158827781.USD","LU2063271972.USD","BK4598","IE00BN8TJ469.HKD","HK0000914686.HKD","SMH","LU2487616109.SGD","LU2237443382.USD","LU0070302665.USD","LU2236285917.USD","LU2211815571.USD","LU2237443895.HKD","LU1934455863.HKD","IE00B1BXHZ80.USD","SG9999014559.SGD","LU0985481810.HKD","LU0444973449.USD","LU2931357623.SGD","LU1003077747.HKD","NVIW.SI","LU0882574139.USD","LU0011850046.USD","CLSE","IE00BDGV0183.EUR","LU2168564222.USD","AAUM","LU0788109477.HKD","LU2347655073.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969540","title":"施贵宝将斥资23亿美元在休斯顿新建生产设施","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969540","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969540?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:41","pubTimestamp":1786419695,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00B2B36J28.USD","BK4007","LU0306807586.USD","LU1983299246.USD","LU1868837136.USD","IE00BFXG1179.USD","BK4532","IHE","LU1868836591.USD","BMY","LU1868836757.USD","LU0237698245.USD","LU0096364046.USD","LU0432979614.USD","LU2242652126.USD","LU2125154778.USD","LU2133065610.SGD","LU2125154935.USD","BK4581","LU0306806265.USD","LU0985481810.HKD","LU1323610961.USD","LU1074936037.SGD","LU1883839398.USD","LU0321505868.SGD","IE00BJT1NW94.SGD","BK4588","LU1093756168.USD","LU1032466523.USD","LU1868836914.USD","LU0456855351.SGD","BK4559","LU0061475181.USD","LU1989771016.USD","IE00BSNM7G36.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0267386448.USD","LU1093756325.SGD","LU1261432733.SGD","LU1670710588.SGD","LU0321505439.SGD","LU1291159041.SGD","LU1571399168.USD","LU2596442595.SGD","LU1430594728.SGD","LU1868837300.USD","LU2360032135.SGD","FTXH","LU1670711123.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183112553","title":"百时美施贵宝斥资23亿美元在休斯敦建设制药基地，扩大美国制造布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1183112553","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183112553?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:23","pubTimestamp":1786368216,"startTime":"0","endTime":"0","summary":" $施贵宝(BMY)$宣布，将投入约23亿美元，在美国得克萨斯州休斯敦建设一座新的制药生产基地，以扩大其美国制造能力。","market":"us","thumbnail":"https://community-static.tradeup.com/news/a1656cfd2a6cd4b8dbc594f7f4f54ed3","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/a1656cfd2a6cd4b8dbc594f7f4f54ed3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1173574888","title":"施贵宝大手笔投入23亿美元，得州休斯顿新建美国制造园区","url":"https://stock-news.laohu8.com/highlight/detail?id=1173574888","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173574888?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:03","pubTimestamp":1786367005,"startTime":"0","endTime":"0","summary":"施贵宝（Bristol Myers Squibb）正加速推进其在美国本土的制造布局，斥资23亿美元，在得克萨斯州休斯顿打造全新园区。这一举措标志着该公司在强化国内生产能力上的重大战略转折。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4534","LU2242646821.SGD","LU1670711123.USD","LU1032466523.USD","LU1868836591.USD","LU1868836757.USD","LU1670711040.USD","LU1883839398.USD","BK4532","IE00BJJMRZ35.SGD","LU0061475181.USD","FTXH","BK4581","LU1670710588.SGD","LU2360032135.SGD","LU0456855351.SGD","LU2596442595.SGD","LU1983299246.USD","LU2125154935.USD","LU2133065610.SGD","LU0432979614.USD","LU1868837136.USD","LU0985481810.HKD","BMY","IE00BJT1NW94.SGD","LU0237698245.USD","LU0882574055.USD","LU1868837300.USD","BK4588","LU1989771016.USD","LU1571399168.USD","IE00BSNM7G36.USD","LU0306807586.USD","LU1074936037.SGD","LU0321505439.SGD","LU1291159041.SGD","LU1430594728.SGD","LU1585245621.USD","LU1718418525.SGD","LU0096364046.USD","IE0002141913.USD","IE0009355771.USD","LU2125154778.USD","IE00BFXG1179.USD","LU1868836914.USD","BK4007","LU0114720955.EUR","LU0306806265.USD","IE00BFTCPJ56.SGD","BK4559","LU0225284248.USD","LU1670710661.SGD","LU1093756325.SGD","LU0868494617.USD","LU0225771236.USD","LU1323610961.USD","BK4585","LU2242652126.USD","LU1261432733.SGD","LU0321505868.SGD","IE00B2B36J28.USD","IHE","LU0267386448.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195598895","title":"施贵宝预计2027-2030年间将创造2000个建筑与间接就业岗位","url":"https://stock-news.laohu8.com/highlight/detail?id=1195598895","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195598895?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:02","pubTimestamp":1786366963,"startTime":"0","endTime":"0","summary":"施贵宝公司（Bristol-Myers Squibb）近日宣布，其计划在2027年至2030年期间，通过一系列项目带动约2000个建筑相关岗位及间接就业机会的诞生。这一举措，无疑将为地区经济注入新的活力。从长远来看，这些岗位不仅涵盖直接的建筑施工，还包括围绕项目产生的各类配套服务与供应链支持。施贵宝此番布局，彰显了其对未来发展的坚定信心，以及持续扩大业务版图的战略雄心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","BMY","LU1989771016.USD","LU1670711040.USD","LU1585245621.USD","LU1291159041.SGD","LU1868836757.USD","BK4534","LU1323610961.USD","BK4007","LU0061475181.USD","LU0225771236.USD","IE00BJT1NW94.SGD","LU1074936037.SGD","LU2242652126.USD","IE0002141913.USD","LU1571399168.USD","LU0306807586.USD","IE00B2B36J28.USD","LU0306806265.USD","LU1868837300.USD","LU2133065610.SGD","BK4588","IE00BFXG1179.USD","LU0267386448.USD","LU1093756325.SGD","LU1670711123.USD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU2125154935.USD","LU0237698245.USD","LU0321505868.SGD","FTXH","LU2360032135.SGD","LU1261432733.SGD","LU1868837136.USD","LU1032466523.USD","LU0882574055.USD","LU0868494617.USD","LU1883839398.USD","LU0456855351.SGD","IE0009355771.USD","BK4585","LU0321505439.SGD","IHE","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU1093756168.USD","LU1670710661.SGD","LU0432979614.USD","LU1868836591.USD","LU1868836914.USD","BK4581","LU0114720955.EUR","LU1983299246.USD","LU1718418525.SGD","LU1670710588.SGD","LU0985481810.HKD","LU2242646821.SGD","LU2596442595.SGD","LU0225284248.USD","LU0096364046.USD","BK4532","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134949088","title":"Prothena有望获5500万美元临床里程碑付款——取决于施贵宝是否推动PRX019项目，预计2026年底揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1134949088","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134949088?lang=zh_cn&edition=full","pubTime":"2026-08-07 05:11","pubTimestamp":1786050676,"startTime":"0","endTime":"0","summary":"Prothena公司透露，若百时美施贵宝决定推进PRX019项目，其有望获得一笔高达5500万美元的临床里程碑付款。而施贵宝的这项决策，预计将在2026年年底前作出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","LU1074936037.SGD","LU1261432733.SGD","LU1670711123.USD","LU1868836591.USD","LU2242646821.SGD","LU0225284248.USD","LU0432979614.USD","BK4581","LU0306807586.USD","LU0882574055.USD","BK4139","LU0321505439.SGD","LU2125154935.USD","LU0114720955.EUR","LU1670710661.SGD","IE00BSNM7G36.USD","IE00BFXG1179.USD","LU1291159041.SGD","LU2596442595.SGD","BK4559","LU2242652126.USD","LU2125154778.USD","LU0985481810.HKD","LU1670710588.SGD","LU1868836757.USD","LU1883839398.USD","BK4007","BK4588","IHE","BMY","LU1032466523.USD","LU1093756168.USD","LU0321505868.SGD","LU1868837136.USD","LU1868837300.USD","LU1670711040.USD","PRTA","LU2133065610.SGD","LU1868836914.USD","LU2360032135.SGD","LU1983299246.USD","LU0456855351.SGD","BK4532","LU0225771236.USD","LU0237698245.USD","BK4534","IE00BFTCPJ56.SGD","LU1989771016.USD","IE0009355771.USD","LU0267386448.USD","LU0306806265.USD","LU1093756325.SGD","LU0868494617.USD","FTXH","BK4585","LU0061475181.USD","LU1323610961.USD","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU1585245621.USD","IE00B2B36J28.USD","LU1571399168.USD","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162455676","title":"异动解读｜施贵宝盘中下跌3.19%，知情人士否认与阿斯利康合并传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=1162455676","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162455676?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:50","pubTimestamp":1785937812,"startTime":"0","endTime":"0","summary":"8月5日，施贵宝盘中下跌3.19%，报63.475美元/股，成交额1.54亿美元。消息面上，一位接近此事的高层消息人士透露，阿斯利康与施贵宝之间\"从来就没有什么交易可谈\"，双方未就潜在合并进行任何讨论。此前RBC Capital Markets亦发布研报指出，阿斯利康股东可能普遍反对该组合，多数投资者认为交易概率极低，部分投资者将此前报道视为\"试探气球\"。施贵宝此前因合并传闻上涨逾4%，随着交易前景趋于否定，股价回吐涨幅。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"施贵宝盘中下跌3.19%，知情人士否认与阿斯利康合并传闻","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540291","title":"美股异动｜阿斯利康反弹涨超4%，消息人士否认与施贵宝合并传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540291","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657540291?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:46","pubTimestamp":1785937567,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","LU0114720955.EUR","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU2237443549.SGD","LU2242646821.SGD","LU0456855351.SGD","LU0289739699.SGD","LU1718418525.SGD","LU0058720904.USD","LU1093756168.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","FTXH","LU2125154935.USD","IE00BFXG1179.USD","AZN","BK4585","LU2133065610.SGD","LU1989771016.USD","LU1868836914.USD","IHE","LU1093756325.SGD","LU0320765992.SGD","LU1670711040.USD","LU0882574055.USD","LU1983299246.USD","LU0267386448.USD","LU1868836591.USD","BK4581","LU0985481810.HKD","LU1829250122.USD","LU2236285917.USD","LU1868837136.USD","LU0237698245.USD","BMY","LU0306806265.USD","LU2462157665.USD","LU0096364046.USD","BK4568","AZNH","LU1267930573.SGD","BK4559","IE0009355771.USD","LU2237443622.USD","LU2242652126.USD","LU0029864427.USD","LU0889565916.HKD","LU1585245621.USD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542821","title":"阿斯利康股价大涨，消息称目前未与百时美施贵宝进行并购谈判后，该股日内涨幅现已达到3.5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657542821?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:32","pubTimestamp":1785933172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B2B36J28.USD","LU0868494617.USD","LU0058720904.USD","AZNH","BK4559","IE00BFTCPJ56.SGD","BK4588","LU0128525929.USD","XMMO","LU0306807586.USD","IE0009355771.USD","KCE","LU0889565916.HKD","LU1430594728.SGD","LU1868836914.USD","CALF","MYLD","LU0267386448.USD","LU0310800379.SGD","IE00BSNM7G36.USD","LU0321505439.SGD","LU2242646821.SGD","LU1261432733.SGD","BK4007","BK4585","IE00B3T34201.USD","LU1829250122.USD","LU0061475181.USD","LU2242652126.USD","AZN","LU0882574055.USD","LU1093756325.SGD","LU2468319806.SGD","LU0029864427.USD","LU1670710661.SGD","BK4532","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0225284248.USD","LU2237443978.SGD","LU1093756168.USD","LU1868836591.USD","FTXH","IHE","BMY","LU2237443382.USD","IE0002141913.USD","LU2596442595.SGD","LU1868837136.USD","LU2456880835.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111805047","title":"市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论","url":"https://stock-news.laohu8.com/highlight/detail?id=1111805047","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111805047?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:09","pubTimestamp":1785931786,"startTime":"0","endTime":"0","summary":"8月5日，阿斯利康盘前涨超5%、施贵宝跌近3%；消息人士表示双方之间没有就潜在交易进行任何讨论。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"市场消息：阿斯利康与施贵宝之间没有就潜在交易进行任何讨论","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544514","title":"百时美施贵宝股价盘前交易迅速下跌2.3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657544514?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:09","pubTimestamp":1785931781,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1430594728.SGD","LU2133065610.SGD","IE00BJJMRZ35.SGD","LU1032466523.USD","LU1093756168.USD","BK4532","LU0306806265.USD","LU0061475181.USD","LU0096364046.USD","LU0456855351.SGD","IE0009355771.USD","LU1093756325.SGD","LU2242646821.SGD","LU2125154935.USD","LU1291159041.SGD","IE0002141913.USD","LU0306807586.USD","LU1261432733.SGD","LU1323610961.USD","LU1868837300.USD","LU1868837136.USD","LU1571399168.USD","BK4588","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU0225284248.USD","IHE","IE00BFXG1179.USD","LU0267386448.USD","BK4534","LU0985481810.HKD","LU1883839398.USD","LU1983299246.USD","LU1989771016.USD","LU0882574055.USD","LU2596442595.SGD","LU2125154778.USD","LU1585245621.USD","LU1868836757.USD","LU0225771236.USD","LU0321505868.SGD","BMY","LU0237698245.USD","LU1670710588.SGD","BK4007","LU1868836914.USD","LU1868836591.USD","BK4585","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107785089","title":"异动解读｜施贵宝盘前下跌3.14%，RBC称与阿斯利康合并可能性极低","url":"https://stock-news.laohu8.com/highlight/detail?id=1107785089","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107785089?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:06","pubTimestamp":1785931613,"startTime":"0","endTime":"0","summary":"8月5日，施贵宝盘前下跌3.14%，报64.2美元/股，成交额115.12万美元。消息面上，RBC Capital Markets发布研报指出，阿斯利康与百时美施贵宝的合并谈判不太可能达成交易，主要因阿斯利康股东可能普遍反对该组合，多数投资者认为交易概率较低。RBC称阿斯利康股东质疑交易合理性并对增长前景表达担忧，部分投资者将此前报道视为\"试探气球\"，最终可能被放弃。此前施贵宝曾因合并传闻上涨逾4%，随着交易前景趋于悲观，股价回吐涨幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"施贵宝盘前下跌3.14%，RBC称与阿斯利康合并可能性极低","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154786832","title":"独家消息：知情高层透露，阿斯利康与施贵宝之间“从未有过交易可谈”","url":"https://stock-news.laohu8.com/highlight/detail?id=1154786832","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154786832?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:04","pubTimestamp":1785931452,"startTime":"0","endTime":"0","summary":"独家消息——一位接近此事的高层消息人士透露，阿斯利康制药（AstraZeneca PLC）与施贵宝（Bristol-Myers Squibb）之间“从来就没有什么交易可谈”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0114720955.EUR","LU1267930813.SGD","LU1078025761.USD","LU2293690249.USD","LU1019634622.SGD","LU1074936037.SGD","LU0526926950.USD","LU1989771016.USD","LU0128525689.USD","LU0390134368.USD","LU0949170772.SGD","LU0122379950.USD","LU0868494617.USD","LU1829250122.USD","IHE","LU2242646821.SGD","LU1481599808.USD","LU0784384876.USD","SG9999001176.SGD","LU1481600234.SGD","LU1880407132.USD","LU1571399168.USD","LU1061106388.HKD","LU2089283258.USD","LU1868837300.USD","IE00B4R5TH58.HKD","LU0211328371.USD","LU1291159041.SGD","BK4559","BK4534","LU0321505439.SGD","LU0203345920.USD","LU0920840948.USD","LU0857590862.USD","LU0321505868.SGD","LU1718418525.SGD","LU0058720904.USD","LU2433249047.HKD","LU1196032939.SGD","LU2112291526.USD","LU1496350502.SGD","LU0963555726.SGD","LU0211326755.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","LU0997586432.USD","LU0225771236.USD","LU0310800965.SGD","LU1989772840.SGD","LU0553294199.USD","LU0708994859.HKD","IE00B2B36J28.USD","LU2023251221.USD","LU2242652126.USD","LU0920783379.SGD","LU1670711123.USD","LU1273509221.SGD","LU0784385840.USD","LU0661504455.SGD","LU1863844665.USD","LU0827474353.SGD","LU0997586515.USD","LU1153585028.USD","BK4581","LU0128525929.USD","LU1153584641.USD","LU1003076772.USD","LU0345777147.USD","LU1093756325.SGD","LU0972486137.USD","LU1355424745.HKD","LU0061475181.USD","LU2293690082.USD","LU0882574055.USD","LU1814569148.SGD","SG9999013999.USD","LU0887340254.USD","LU0757432116.USD","IE00BJT1NW94.SGD","LU1880407215.USD","LU2360032135.SGD","LU0266013472.USD","IE0002141913.USD","LU0575583348.USD","SGXZ57979304.SGD","LU1057294990.SGD","LU2355687059.USD","LU0171293334.USD","LU2237443622.USD","LU1868836757.USD","BMY","LU2125154778.USD","LU0345777659.USD","LU1064927863.SGD","LU2089284900.SGD","LU1261432733.SGD","LU1863844749.USD","LU1923622614.USD","LU0964806797.USD","LU0784385170.HKD","LU2237443895.HKD","LU0640478417.SGD","LU2108987350.USD","LU0237698245.USD","LU0738911758.USD","LU1019632923.USD","AZN.UK","LU0052756011.USD","LU1430594728.SGD","BK5011","LU0047473722.SGD","LU0171276677.USD","LU1496350171.SGD","LU2125154935.USD","LU2596442595.SGD","LU0306807586.USD","BK4588","LU1051770623.HKD","LU2125909593.SGD","IE00BFXG1179.USD","LU1119994496.HKD","LU1093756168.USD","LU1267930227.SGD","LU2279689827.SGD","SG9999001176.USD","LU2324357040.USD","LU0823399737.USD","LU0859254822.USD","LU1267930573.SGD","IE00BSNM7G36.USD","LU0011850046.USD","LU0949170426.SGD","LU2539964713.USD","LU1301847155.USD","LU0077335932.USD","LU2468319806.SGD","LU0499090636.EUR","LU0306806265.USD","LU1170363599.USD","LU1323610961.USD","LU0096364046.USD","LU0267386448.USD","LU1989772923.USD","LU1868836591.USD","LU1104425308.USD","LU0889565080.SGD","LU1015430645.USD","LU0225284248.USD","IE00B3T34201.USD","LU1023059063.AUD","LU0158827948.USD","LU0957799991.USD","LU1267930490.SGD","LU1084165304.USD","IE00BJJMRZ35.SGD","LU2237443978.SGD","LU1003077747.HKD","LU2237443465.HKD","LU1670710661.SGD","LU2237443382.USD","IE0034235188.USD","BK4585","LU1046234339.USD","LU0969580561.USD","LU2357627491.SGD","LU2125909247.SGD","LU1983299246.USD","LU0310799852.SGD","03165","LU0047473722.EUR","LU0784383803.USD","IE0009355771.USD","LU0456855351.SGD","LU0557290698.USD","LU1670711040.USD","LU0211327993.USD","LU0985481810.HKD","LU1868836914.USD","LU2133065610.SGD","IE00BKPKM643.USD","LU0203347892.USD","LU0432979614.USD","LU1883839398.USD","LU0960981461.USD","LU2237443549.SGD","LU1487256676.USD","BK4532","FTXH","LU0029864427.USD","LU0211326839.USD","LU0496365809.HKD","LU0976567544.SGD","LU3187612489.SGD","LU0545039389.USD","LU0889566641.SGD","LU1868837136.USD","LU1670710588.SGD","LU0792757196.USD","LU0823416689.USD","LU2114397693.USD","LU1032466523.USD","LU2089984988.USD","LU2091194634.USD","LU0289739699.SGD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.1352},{"period":"3month","weight":0.1342},{"period":"6month","weight":0.0644},{"period":"1year","weight":0.3511},{"period":"ytd","weight":0.1986}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.005808},{"month":5,"riseRate":0.553191,"avgChangeRate":0.001393},{"month":6,"riseRate":0.617021,"avgChangeRate":0.009381},{"month":7,"riseRate":0.425532,"avgChangeRate":0.001143},{"month":8,"riseRate":0.510638,"avgChangeRate":-0.001216},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}